文献速递肺血管病与心包/心肌炎心力衰竭与心肌病

长链非编码RNA H19作为肺动脉高压右心衰竭的新生物标志物与治疗靶点

Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension.
PubMed 文献 · Circulation · 2020-07-23

该研究在肺动脉高压患者右心室组织与血浆中评估长链非编码RNA H19的表达,并在两种大鼠右心衰竭模型中探索沉默H19的作用。结果显示失代偿右心室中H19上调并与肥厚和纤维化相关,沉默H19可保留右心室功能而不影响肺血管重塑;血浆H19可区分患者与对照、与右心室功能相关并预测长期生存。

要点

  • 失代偿性右心室中H19表达上调,与右心室肥厚和纤维化相关。
  • 沉默H19可减轻大鼠右心室病理重塑并保留右心室功能,不影响肺血管重塑。
  • 血浆H19可区分肺动脉高压患者与对照,与右心室功能相关并预测长期生存。

核心结论

  • H19是阻碍适应不良性右心室重塑的新治疗靶点,也是有前景的肺动脉高压严重程度与预后生物标志物。

研究设计与样本

  • 研究采用定量PCR检测患者血浆和右心室中H19表达,患者按临床病史和心指数分为对照右心室、代偿右心室和失代偿右心室。
  • 使用GapmeR抑制H19,在野百合碱和肺动脉环缩两种模拟右心衰竭的大鼠模型中开展超声心动图、血流动力学、组织学和生化分析。
  • 在大鼠心肌细胞中进行了体外功能获得与功能缺失实验。
  • 在2个独立特发性肺动脉高压队列中评估血浆H19对长期生存的预测价值。

主要发现

  • 失代偿右心室中H19上调,并与右心室肥厚和纤维化相关;野百合碱和肺动脉环缩大鼠中观察到类似发现。
  • 沉默H19限制了右心室病理性的肥厚、纤维化和毛细血管稀疏,从而在野百合碱和肺动脉环缩大鼠中保留右心室功能,且不影响肺血管重塑。
  • 该心脏保护作用伴随E2F转录因子1介导的zeste同源增强子2上调。
  • 体外敲低H19抑制苯肾上腺素诱导的心肌细胞肥厚,而过表达则产生相反效应。
  • 血浆H19水平可区分肺动脉高压患者与对照,与右心室功能相关,并在2个独立特发性肺动脉高压队列中预测长期生存;与NT-proBNP或REVEAL及2015年欧洲肺动脉高压指南风险评分联合时,可区分预后不同的亚组。

临床怎么用

  • 血浆H19有望作为肺动脉高压严重程度和预后的生物标志物,并可结合NT-proBNP或风险评分进行风险分层。
  • 抑制H19可能成为阻碍适应不良性右心室重塑的治疗策略,但尚需临床研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Right ventricular (RV) function is the major determinant for both functional capacity and survival in patients with pulmonary arterial hypertension (PAH). Despite the recognized clinical importance of preserving RV function, the subcellular mechanisms that govern the transition from a compensated to a decompensated state remain poorly understood and as a consequence there are no clinically established treatments for RV failure and a paucity of clinically useful biomarkers. Accumulating evidence indicates that long noncoding RNAs are powerful regulators of cardiac development and disease. Nonetheless, their implication in adverse RV remodeling in PAH is unknown. METHODS: Expression of the long noncoding RNA H19 was assessed by quantitative PCR in plasma and RV from patients categorized as control RV, compensated RV or decompensated RV based on clinical history and cardiac index. The impact of H19 suppression using GapmeR was explored in 2 rat models mimicking RV failure, namely the monocrotaline and pulmonary artery banding. Echocardiographic, hemodynamic, histological, and biochemical analyses were conducted. In vitro gain- and loss-of-function experiments were performed in rat cardiomyocytes. RESULTS: We demonstrated that H19 is upregulated in decompensated RV from PAH patients and correlates with RV hypertrophy and fibrosis. Similar findings were observed in monocrotaline and pulmonary artery banding rats. We found that silencing H19 limits pathological RV hypertrophy, fibrosis and capillary rarefaction, thus preserving RV function in monocrotaline and pulmonary artery banding rats without affecting pulmonary vascular remodeling. This cardioprotective effect was accompanied by E2F transcription factor 1-mediated upregulation of enhancer of zeste homolog 2. In vitro, knockdown of H19 suppressed cardiomyocyte hypertrophy induced by phenylephrine, while its overexpression has the opposite effect. Finally, we demonstrated that circulating H19 levels in plasma discriminate PAH patients from controls, correlate with RV function and predict long-term survival in 2 independent idiopathic PAH cohorts. Moreover, H19 levels delineate subgroups of patients with differentiated prognosis when combined with the NT-proBNP (N-terminal pro-B-type natriuretic peptide) levels or the risk score proposed by both REVEAL (Registry to Evaluate Early and Long-Term PAH Disease Management) and the 2015 European Pulmonary Hypertension Guidelines. CONCLUSIONS: Our findings identify H19 as a new therapeutic target to impede the development of maladaptive RV remodeling and a promising biomarker of PAH severity and prognosis.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Omura J, Habbout K, Shimauchi T, et al. Identification of Long Noncoding RNA H19 as a New Biomarker and Therapeutic Target in Right Ventricular Failure in Pulmonary Arterial Hypertension. Circulation. 2020. PMID: 32698630. doi:10.1161/CIRCULATIONAHA.120.047626

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。